This retrospective, observational cohort study used administrative medical and pharmacy claims data of patients with CD or UC from HealthCore Integrated Research Database (HIRD). Judith STEPHENSON | Principal Scientist | Research profile We accessed administrative claims data from the HealthCore Integrated Research Database, which contains longitudinal claims from 8 health insurance plans in all regions of the United States. Identification of inadequate responders to advanced therapy among IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. One example would be the interaction of biomarker testing, treatment choice, and health outcomes. A real-world study on characteristics, treatments and outcomes in US The integration of data from disparate sources could help alleviate data insufficiency in real-world studies and compensate for the inadequacies of single data sources and short-duration, small sample size studies while improving the utility of data for research. National Library of Medicine meaningful and actionable findings. View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005304/en/, Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732, Nick Childs, IQVIA Investor Relations (nicholas.childs@iqvia.com) +1.973.316.3828. Real-world evidence (RWE), which is largely derived from big health care data, has increasingly been driven by important technological advances, including machine learning, natural language processing improvements in electronic medical systems, and the ability to link clinical and health claims data in private and public systems [9]. aIndicates variable was sourced from the data set listed in the column header. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. For example, integrated data allow the inclusion of important clinical factors when analyzing health care utilization and costs, as recorded in claims [13]. to improve insights and decision making in healthcare.. Realizing the benefits for healthcare requires the right expertise. Each member operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization . data, the HealthCore team will have the ability to use its broader Clinical research: Designs and executes clinical trials from start-up to closeout to drive needed therapies and meaningful outcomes. Proceedings published by the National Academies of Sciences, Engineering, and Medicine chronicle the presentations and discussions at a workshop, symposium, or other event convened by the National Academies. Once obtained and screened, clinical information was abstracted from each record by trained health information management technicians using a standardized form. This study was conducted in full compliance with the relevant provisions of the Health Insurance Portability and Accountability Act. To learn more, visit www.iqvia.com. 2023 Apr 8;15:251-267. doi: 10.2147/CEOR.S401003. Parlett LE, Beachler DC, Lanes S, Hoover RN, Cook MB. This retrospective cohort study integrated data from 4 sources: administrative claims from the HealthCore Integrated Research Database, clinical data from a Cancer Care Quality Program (CCQP), clinical data from abstracted medical records (MRs), and mortality data from the US Social Security Administration. . Int J Appl Basic Med Res. variety of health care decisions. This evolving environment, along with growing interest in PCTs, is increasing the importance of big data and RWE as a complement to RCTs [36,37]. CCQP offers incentives to physicians for treating according to evidence-based guidelines created by the health plan, which could have influenced treatment choices. Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality. outcomes research subsidiary of Anthem, Inc. We work with life sciences Oncologists' views regarding the role of electronic health records in care coordination. It is mandatory to procure user consent prior to running these cookies on your website. Careers, Unable to load your collection due to an error. Patients were aged at least 40 years with a diagnosis of COPD (but not asthma) at cohort entry. The mean duration of 1L therapy was 128 (median 90) days; 56.84% (1122/1974) switched to 2L therapy with a gap 90 days and 43.16% (852/1974) had a gap of >90 days before initiating 2L. Validation of a case-finding algorithm for identifying patients with Non-small Cell Lung Cancer (NSCLC) in administrative claims databases. Hess LM, Kern DM, Carter GC, Winfree K, Wang L, Sontag A, Oton AB. Internet Explorer presents a security risk. 8600 Rockville Pike Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK. HealthCore is now Carelon Research. Holistic View of Autografting Patients by Percentage of Total Body Surface Area Burned: Medical Record Abstraction Integrated with Administrative Claims. HIRD - HealthCore Integrated Research Database - All Acronyms Clipboard, Search History, and several other advanced features are temporarily unavailable. (III/IV) ovarian cancer patients in the US diagnosed from 2010 to 2018 in the HealthCore Integrated Research Database (HIRD) using a validated predictive model algorithm. All patients identified in the CCQP data were also included in the HIRD sample; patients who appeared in the HIRD but not the CCQP were retained. Methods Adults with 2 claims with depression diagnosis codes identified from the HealthCore Integrated Research Database were invited to participate in this study linking survey data with . Garon EB, Ciuleanu T, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim J, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Prol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. We can determine the right questions to ask, design studies to provide comprehensive answers, and translate and deliver meaningful results necessary for impactful decisions across the healthcare continuum from treatment development through care delivery and policy. Methods: These cookies will be stored in your browser only with your consent. 1 Together, we can solve customer challenges and improve patient lives. This category only includes cookies that ensures basic functionalities and security features of the website. Data were extracted from medical, pharmacy, and eligibility databases. Our ability to link data using deterministic matching enables our teams to design, conduct, and analyze complex data in ways that others cannot. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel J, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Most HealthCore de-identified claims and clinical data have been incorporated into the IQVIA PharMetrics Plus data source, resulting in a substantial patient volume increase. With more than 20 years of experience, clinical and scientific research expertise, and exclusive access to a robust, integrated research environment containing information on nearly 60 million individuals from multiple health plans across the U.S., HealthCore delivers unparalleled clarity and actionable information to health care decision makers. Descriptive and univariate statistics were reported. This study aims to describe and evaluate a process of integrating data from several complementary sources to conduct health outcomes research in patients with non-small cell lung cancer (NSCLC). Please enable it to take advantage of the complete set of features! Will Gen AI Help the Texas Rangers Win the World Series in 23? fit into treatment patterns, whether their products impact the correct In addition, large RWE studies are invaluable in detecting the side effects of treatments over longer periods. Nadler E, Espirito JL, Pavilack M, Boyd M, Vergara-Silva A, Fernandes A. Epub 2021 Aug 28. Height and weight were available for the majority (341/407, 83.8% height; 371/407, 91.2% weight) of patients; mean BMI was 26.1 (SD 6.36). Follow-up will start at the date of the first . RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA (NYSE: IQV) announces its strategic collaboration with HealthCore, Inc., a leading real world research organization in the United States, to advance real world evidence (RWE) studies with increased quality and efficiency. Baseline was defined as the 6 months before the index date (start of 2L therapy). Mark has been extensively involved in healthcare research for more than 25 years. Clopidogrel use and clinical events after drug-eluting stent Follow Carelon Research on LinkedIn to see how our leaders are solving todays most complex health challenges. Furthermore, a bigger role for RWE is developing in decision making across the health care system, including regulators, payers, providers, and patients. Treatment modalities for advanced and/or metastatic NSCLC include radiotherapy, chemotherapy, targeted therapy, or a combination therapy [24]. Assessing bias in administrative database studies of RotaTeq vaccine We are so pleased to be working with IQVIA to enhance its data environment and further our relationship through collaboration on progressive research designs, such as synthetic control arm studies, pragmatic clinical trials, decentralized clinical trials and COVID-19 focused research, said Mark Cziraky, president, HealthCore. Hiangkiat TAN | Director | HealthCore, Wilmington | HEOR | Research profile IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. This is an open-access article distributed under the terms of the Creative Commons Attribution License (. This study included incident advanced stage ovarian cancer patients in the US using the HealthCore Integrated Research Database (HIRD). https://linkinghub.elsevier.com/retrieve/pii/S1098-3015(10)60470-6. http://www.ijabmr.org/article.asp?issn=2229-516X;year=2015;volume=5;issu https://ascopubs.org/doi/10.1200/CCI.18.00156?url_ver=Z39.88-2003&rfr_id Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Objective: Clinical Oncology Research Solutions | Carelon Research Patient sample sizes available for analysis diminish when multiple data sources are required. Ma Q, Chung H, Shambhu S, Roe M, Cziraky M, Jones WS, Haynes K. Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health. MR data may be underreported or missing due to vague, incomplete, or illegible entries; the inability to locate the required information; or missing patient files. A Tabor Communications Publication. exclusive access to a robust, integrated research environment containing Federal government websites often end in .gov or .mil. Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, VanderWalde NA. Turner RM, Chen Y, Fernandes AW. perform clinical record review and validation, and design and implement Healthcore Integrated Research Database - How is Healthcore Integrated Research Database abbreviated? Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data. The generalizability of claims-based results is confined to similarly insured populations (eg, commercial, US-based in this study). government site. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. comparative safety and efficacy analyses. Weve reached across tables and stakeholder lines to help inform and improve policies, programs, guidelines, best practices, and more for decision makers and patients. 2019 May;3:119. 2017 Oct 30;15(1):193. doi: 10.1186/s12916-017-0954-x. "Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Classifying Stage IV lung cancer from health care claims: a comparison of multiple analytic approaches. Clopidogrel Use and Clinical Events After Drug-Eluting Stent Wu J, Tan Y, Chen Z, Zhao M. Decision based on big data research for non-small cell lung cancer in medical artificial system in developing country. As a member of the Carelon family of companies under Elevance Health, we have an opportunity to amplify the impact of research as a critical component and driver of Carelons goal of better solving complex challenges in healthcare. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners. Second, lung cancer diagnosis and treatment claims were used to identify patients with 2L treatment in the HIRD. WILMINGTON, Del., May 29, 2018 Life sciences companies can for the first time access one of the largest commercially insured population databases in the United States and find answers faster and more cost-effectively to questions, including whether theyre targeting the right populations for clinical trials, with the launch of HealthCores integrated database through Boston Health Economics Instant Health Data platform. HHS Vulnerability Disclosure, Help 2021 Dec;8(4):577-587. doi: 10.1007/s40801-021-00269-0. "Global Consumer Health Trends 2023 Webinar Series, "Capturing value at scale: The $4 billion RWE imperative. the treatment paradigm, assess unmet need, and perform complex IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions. We quantified SSTI incidence, type, and complications and comparative incidence trends for . Simeone JC, Nordstrom BL, Patel K, Klein AB. HealthCore. Comparison Between Health Insurance Claims and Electronic Health Records (EHRs) for Metastatic Non-small-cell Lung Cancer (NSCLC) Patient Characteristics and Treatment Patterns: A Retrospective Cohort Study. Board on Health Sciences Policy. Wilmington, DE, Houston KA, Henley SJ, Li J, White MC, Richards TB. Occurrence of adverse events among patients with inflammatory - PubMed For the claims-only cohort, the mean age was 66.6 (SD 12.69) years, 52.1% (485/931) were female, the median length of follow-up was 8.6 months, and for 29.3% (273/931), death was observed. See Full PDF Download PDF. IQVIA is committed to enhancing evidence generation with the goal of advancing patient health and clinical outcomes.. Fair Billing Practice. statistical analyses, and produce reports all in an easy-to-use Conflicts of Interest: MG is an employee of HealthCore, Inc, an independent research organization that received funding from Eli Lilly and Company for the conduct of this study. As treatments in oncology have improved, patients with lung cancer are living longer with the ability to personalize care with novel targeted therapies. Were committed to supporting the need for evidence generation and research collaboration in the marketplace, and delivering the expertise, unparalleled data, relationships, and evidence-generation capabilities long valued by our partners and clients in life sciences, government, and academia. For example, medical records (MRs) generally do not contain details of care outside of the point of service of the single health care provider, claims data contain few variables related to clinical outcomes, and registries often do not contain complete longitudinal data [4-7]. Other: Multimodal intervention strategy National Library of Medicine Treatment patterns from Cancer Care Quality Program and claims, measured from the initiation of first-line treatment to the end of follow-up. 2022 Jun 8;27(6):e484-e493. Were also uniquely positioned to provide evidence-based insights back to Elevance Health through innovative research solutions and multi-stakeholder collaborations. Published In In the main analysis cohort, additional clinical information was available via CCQP and/or MRs (Table 5). investigations on de-identified data from patients using products in the A validation of clinical data captured from a novel Cancer - PubMed At Carelon Research, we help improve the future of healthcare with trusted insights powered by evidence. The benefit of using both claims data and electronic medical record data in health care analysis. Specific to the data used for this project, limitations include the following: CCQP data were collected at the time of the prior authorization request, not at diagnosis. Leveraging linkage of cohort studies with administrative claims data to identify individuals with cancer. Funding for the study was provided to HealthCore, Inc by Eli Lilly and Company. 40+ financial datasets, pre-integrated in Apperate. Herbst RS, Baas P, Kim D, Felip E, Prez-Gracia JL, Han J, Molina J, Kim J, Arvis CD, Ahn M, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Health Economics Instant Health Data Platform will enable our clients Incidence of skin and soft tissue infections in ambulatory and - PubMed Among the 407 patients with MR data, 45.7% (186/407) were White, 3.7% (15/407) were Black, 3.2% (13/407) were other races, and 47.4% (193/407) had no race information. HealthCore Announces First-Time Direct Access to its Research Data Methods: We examined ambulatory and inpatient data of over 48 million persons years aged 0-64 years from the HealthCore Integrated Research Database (HIRD) between 2005 and 2010. Death (for all causes) was observed in 37.77% (829/2195) of the main analysis cohort and 29.3% (273/931) of the claims-only cohort. IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The most frequent 2L treatment was immunotherapy (1094/2195, 49.84%), followed by platinum-based regimens (472/2195, 21.50%) and single-agent chemotherapy (441/2195, 20.09%); mean duration of 2L therapy was 5.6 (SD 4.9, median 4) months. Asan O, Nattinger AB, Gurses AP, Tyszka JT, Yen TWF. Agiro A, Chen X, Eshete B, Sutphen R, Clark BE, Burroughs CM, Nowell WB, Curtis JR, Loud S, McBurney R, Merkel PA, Sreih AG, Young K, Haynes K. Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. With the current availability of a wide range of newer, more effective systemic therapies, including several novel biologic agents, the use of diverse provider, institutional, and registry databases is increasingly necessary to evaluate outcomes due to the gaps in administrative claims data alone [32-35]. An official website of the United States government. This study combined 3 data sources for the analysis of real-world outcomes in patients with NSCLC, conducting data integration on a large scale across disparate but complementary sources. The .gov means its official. The integration of data from disparate sources could help alleviate data insufficiency in real-world studies and compensate for the inadequacies of single data sources and short-duration, small sample size studies while improving the utility of data for research. Uno H, Ritzwoller DP, Cronin AM, Carroll NM, Hornbrook MC, Hassett MJ. Real world evidence is playing an increasingly important role in healthcare decision making. Khozin S, Abernethy AP, Nussbaum NC, Zhi J, Curtis MD, Tucker M, Lee SE, Light DE, Gossai A, Sorg RA, Torres AZ, Patel P, Blumenthal GM, Pazdur R. Oncologist. Bethesda, MD 20894, Web Policies National Academies of Sciences, Engineering, and Medicine. Details of the RESOUNDS study design and each of these data sources have been published previously [26]. In the main analysis cohort, mean age was 62.1 (SD 9.27) years and 48.56% (1066/2195) were female (Table 3), whereas in the claims-only cohort, mean age was 66.6 (SD 12.69) years and 52.1% (485/931) were female. Data sources: Primary data from the HealthCore Integrated Research Environment (HIRE)-Oncology database and the HealthCore Integrated Research Database (HIRD) were collected between June 1, 2014, and October 31, 2015. Carelon Research, formerly HealthCore, is now a member of the Carelon family of companies under Elevance Health. We are excited to bring the HIRD database to our customers for the very first time, opening up new possibilities for gaining insights from this large, rich patient population using the most widely-adopted real-world data analytics platform, said Joseph Menzin, founder and CEO of Boston Health Economics. All prior studies, to our knowledge, that focused on the United States used 1 or 2 of the following data sources: administrative claims, registry data, or MR. 2007;10(5):32635. organizations to provide real-world evidence in support of a wide Forum on Drug Discovery, Development, and Translation Examining the impact of real-world evidence on medical product development. We'll assume you're ok with this, but you can opt-out if you wish. This descriptive study used the HealthCore Integrated Research Environment (HIRE) to identify overlapping members between 4 disease-specific PPRNs and 14 geographically dispersed commercial health plans. Follow-up for all-cause death events was conducted through March 31, 2019. Eligible patients from the HIRD who did not appear in the CCQP and for whom no MRs were obtained were included in the claims-only cohort (these patients could have any type and stage of lung cancer). Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab. Health economics & outcomes research: Identifies the real-world value of biomedical products and leverages those insights to advance actionable information for stakeholders. Data source and population. TGu@healthcore.com. Race was not available in patients without MRs. Demographic characteristics at baseline (on or close to second-line therapy initiation date). Data collected during MR abstraction may have measurement errors linked to inconsistent coding, transcription, and data transfer errors. aSecond wave included all patients from the first wave. The data from patients with use of pain medication over 12 months follow-up (after the initiation date of advanced therapies) were collected and analyzed. Proceedings published by the National Academies of Sciences, Engineering, and Medicine chronicle the presentations and discussions at a workshop, symposium, or other event convened by the National Academies. Long before real-world evidence was part of the healthcare vernacular, we worked tirelessly to educate the healthcare industry providers, payers, life sciences companies, regulators, and even patients, of the need to support the development, use, and application of the evidence generated from real-world research. TheFreeDictionary HIRD (redirected from Healthcore Integrated Research Database) Copyright 1988-2018 AcronymFinder.com, All rights reserved. Patients who also had claims for other primary cancers were retained. Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc). The maintenance of these data sets requires constant refresh and update, so that the periods of interest to the investigator can be current and available for analysis. As a wholly owned, independently operating subsidiary of Anthem, Inc., we utilize a powerful research ecosystem of expertise, relationships, and data to generate the evidence needed to improve healthcare. Methods: We conducted a retrospective cohort study of IBD patients in the HealthCore Integrated Research Database (HIRD (TM)) between January 2004 and January 2011 to determine rates of AEs in patients with mild and moderate to severe IBD. We're committed to continuing to deliver the expertise, unparalleled data, relationships, and evidence-generation capabilities long valued by our partners and clients. NSCLC and other forms of cancer are increasingly being managed like chronic diseases with a broad range of increasingly effective treatments. eCollection 2023. HealthCore is finding evidence and truth at the core of healthcare. MeSH Ke X, Navaratnam P, Sasane R, Lawrence DFE, Friedman HS, Tulsi BB, Vollmer T. Determinants of high cost in multiple sclerosis patients: a claims and chart review study. We are excited to bring the HIRD database to our customers for the very IQVIA Collaborates with HealthCore to Advance Clinical Research Using Real World Data, https://www.businesswire.com/news/home/20210908005304/en/. Enriched study types often combine secondary data sources, along with primary data collection via chart reviews and other forms of physician or opt-in patient data collection, including patient-reported outcomes. disciplines to generate evidence on how medical advances can improve By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes. sharing sensitive information, make sure youre on a federal Marks experience spans leadership roles in clinical pharmacy practice with a focus on cardiovascular risk management, academics, clinical trial management, health policy, and retrospective and prospective observational research design and conduct. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Brooks GA, Bergquist SL, Landrum MB, Rose S, Keating NL. Wilson J, Bock A. You also have the option to opt-out of these cookies. With approximately 74,000 employees, IQVIA conducts operations in more than 100 countries. Background: Data from a Cancer Care Quality Program are directly integrated with administrative claims data to provide a level of clinical detail not available in claims-based studies, and referred to as the HealthCore Integrated Research Environment (HIRE)-Oncology data. for HealthCore, Inc.Lori McLaughlin317.407.7403lori.mclaughlin2@anthem.com. HealthCore Inc 1 healthcore integrated research database hird 1 Healthcore Integrated Research Database Hird, supplied by HealthCore Inc, used in various techniques. Bradley Hammill. Visit our investor relations site for more information. f2L medications of interest included atezolizumab, docetaxel, erlotinib, nivolumab, pembrolizumab, pemetrexed, or ramucirumab. experience in designing and conducting research that assesses the value interface by allowing them to answer questions about how their products Health and Medicine Division. We work collaboratively to help provide answers to improve outcomes, lives, and communities. The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale. PMC Required fields are marked *. United States. Board on Health Sciences Policy. As part of Elevance Health, we are the direct recipients of our data assets, curated in the Healthcare Integrated Research Database (HIRD).
Babysitting Etiquette, Amtrak Charleston, Wv Schedule, Ala School Calendar San Tan Valley, Sharepoint List Restrict Column Edit, Livonia High School Calendar, Articles H